Hinge Health, Inc.

NYSE:HNGE Stock Report

Market Cap: US$3.9b

Hinge Health Valuation

Is HNGE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HNGE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$127.76
Fair Value
57.9% undervalued intrinsic discount
14
Number of Analysts

Below Fair Value: HNGE ($49.79) is trading below our estimate of fair value ($127.86)

Significantly Below Fair Value: HNGE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HNGE?

Key metric: As HNGE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HNGE. This is calculated by dividing HNGE's market cap by their current revenue.
What is HNGE's PS Ratio?
PS Ratio8.1x
SalesUS$480.79m
Market CapUS$3.91b

Price to Sales Ratio vs Peers

How does HNGE's PS Ratio compare to its peers?

The above table shows the PS ratio for HNGE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4x
CRVL CorVel
4.1xn/aUS$3.7b
OPCH Option Care Health
0.8x8.36%US$4.3b
WGS GeneDx Holdings
9.7x15.98%US$3.5b
PRVA Privia Health Group
1.6x10.66%US$3.0b
HNGE Hinge Health
8.1x15.81%US$3.9b

Price-To-Sales vs Peers: HNGE is expensive based on its Price-To-Sales Ratio (8.1x) compared to the peer average (4x).

Price to Sales Ratio vs Industry

How does HNGE's PS Ratio compare vs other companies in the US Healthcare Industry?

26 CompaniesPrice / SalesEstimated GrowthMarket Cap
COR Cencora
0.2x6.44%US$61.65b
CAH Cardinal Health
0.2x7.82%US$37.27b
CNC Centene
0.1x4.32%US$17.56b
AONC American Oncology Network
0.2xn/aUS$412.79m
HNGE 8.1xIndustry Avg. 1.3xNo. of Companies26PS012345+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HNGE is expensive based on its Price-To-Sales Ratio (8.1x) compared to the US Healthcare industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is HNGE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HNGE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HNGE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HNGE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$49.79
US$63.71
+27.97%
6.06%US$70.00US$56.00n/a14
Oct ’26US$48.75
US$63.36
+29.96%
6.25%US$70.00US$56.00n/a14
Sep ’26US$56.08
US$62.92
+12.20%
5.96%US$70.00US$57.00n/a13
Aug ’26US$44.95
US$49.23
+9.52%
11.41%US$60.00US$41.00n/a13
Jul ’26US$45.31
US$46.00
+1.52%
6.70%US$52.00US$41.00n/a12
US$63.71
Fair Value
15.5% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/12 14:41
End of Day Share Price 2025/10/10 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hinge Health, Inc. is covered by 15 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vikram KesavabhotlaBaird
Saket KaliaBarclays
Bradley SillsBofA Global Research